RA
CLBT icon

Royce & Associates’s Cellebrite CLBT Stock Holding History

Royce & Associates’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
90,085
+37
+0% +$489 0.01% 664
2026
Q1 		$1.24M Hold
90,048
– – 0.01% 633
2025
Q4 		$1.62M Sell
90,048
-3,894
-4% -$69.9K 0.02% 621
2025
Q3 		$1.74M Buy
93,942
+64,049
+214% +$1.01M 0.02% 603
2025
Q2 		$478K Sell
29,893
-152,291
-84% -$2.71M ﹤0.01% 717
2025
Q1 		$3.54M Sell
182,184
-130,000
-42% -$2.74M 0.04% 496
2024
Q4 		$6.88M Sell
312,184
-398,303
-56% -$7.67M 0.06% 416
2024
Q3 		$12M Hold
710,487
– – 0.11% 270
2024
Q2 		$8.49M Sell
710,487
-84,481
-11% -$944K 0.08% 362
2024
Q1 		$8.81M Buy
794,968
+34,268
+5% +$350K 0.08% 363
2023
Q4 		$6.59M Hold
760,700
– – 0.06% 429
2023
Q3 		$5.82M Hold
760,700
– – 0.06% 448
2023
Q2 		$5.48M Buy
760,700
+100,000
+15% +$583K 0.05% 475
2023
Q1 		$4.02M Buy
660,700
+100,000
+18% +$542K 0.04% 535
2022
Q4 		$2.44M Buy
+560,700
New +$2.5M 0.03% 618

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Royce & Associates's CLBT Position: Q2 2026 in Review

Royce & Associates increased its Cellebrite (CLBT) stake by 0.04% in Q2 2026, buying an estimated $489 and bringing the position to 90,085 shares worth $1.32M. The position accounts for 0.01% of the portfolio, ranked #664.

Royce & Associates first reported a position in CLBT in Q4 2022 and has held it in 15 quarters since. The position peaked at $12M in Q3 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Royce & Associates held 90,085 shares of Cellebrite worth $1.32M as of Q2 2026.
  • Royce & Associates bought 37 Cellebrite shares in Q2 2026, an estimated $489.
  • Cellebrite made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #664 holding.
  • Royce & Associates first reported a position in Cellebrite in Q4 2022 and has held it in 15 quarters since.
  • Royce & Associates's Cellebrite position peaked at $12M in Q3 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.